fashion -WSS

fashion

author：knowledge 2025-09-29 19:05:17 - browse：93

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Grail spinoff by Illumina should end disastrous merger attempt

Wikipedia

WSS

Medicare drug price negotiation hasn't dried up venture capital

Francis Collins on trust in science and how Covid communications failed

David Ricks of Eli Lilly: best biopharma CEO of 2023

Can sheer will power keep patients alive in their dying hours?

Why doctors need education on FDA device approval process

Readout Newsletter: The latest on Moderna, Apellis, and Merck

entertainment

fashion

hotspot

Jerome Adams on the need for new antivirals for Covid

Medicare drug price negotiation hasn't dried up venture capital

Duchenne breakthrough therapy leaves behind pioneering families

Prior authorization will have to move faster under new Biden rule

Guidelines to prevent youth baseball injuries need more muscle

Humana cuts profit projections as Medicare Advantage costs soar

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare Advantage beneficiaries sue Humana over algorithm use

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hospitals owned by private equity see complications spike 25%

entertainment

The surgeon had a dilemma only a Nazi medical text could resolve

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Copay coupons to count toward deductibles, after Biden court move

Three trends to watch in biotech in 2024

Why health records don't always know when patients are dead

eGenesis tests gene

leisure time

Wikipedia

explore

knowledge